A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study with a Repeat-Dose Arm to Evaluate the Safety, Tolerability and Pharmacokinetics of Topically Administered PRN473 in Healthy Adult Participants
Latest Information Update: 11 Mar 2022
At a glance
- Drugs Atuzabrutinib (Primary)
- Indications Immunological disorders; Skin disorders
- Focus Adverse reactions
- Sponsors Principia Biopharma
Most Recent Events
- 01 Feb 2022 Planned number of patients changed from 40 to 60.
- 01 Feb 2022 Actual date of last participant enrolled is 20/09/2020 according to Australian New Zealand Clinical Trials Registry record.
- 01 Feb 2022 Status changed from recruiting to completed.